Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 5754-5757, December 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kwak, L. W.
Right arrow Articles by Williams, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kwak, L. W.
Right arrow Articles by Williams, R. M.

H-2 Gene Control of Resistance to P815-X2 Mastocytoma1

Larry W. Kwak, Omer Kucuk, Roger W. Melvold and R. Michael Williams2

Section of Medical Oncology, Departments of Medicine and Microbiology-Immunology and the Cancer Center, Northwestern University Medical School, Chicago, Illinois 60611

Some, but not all, mutations at H-2 loci can alter, in either direction, histocompatible tumor resistance in the model system of P815-X2 mastocytoma (DBA/2 origin) transplanted into DBA/2J or (C57BL/6 x DBA/2J)F1 mice. This hybrid effect has been shown previously to depend on the immune system. We have examined eight mutants at H-2Kb (bm1, bm4, bm6, bm7, bm8, bm10, bm11, and bm16, two at H-2Db (bm13 and bm14), and one I-Ab mutant (bm12). When one parent is an H-2b mutant (C57BL/6 mutant), the hybrid progeny (C57BL/6 mutant x DBA/2J)F1 may have increased (bm7 and bm8) or decreased (bm10, bm11, bm12, and bm16) survival times when compared to (C57BL/6 x DBA/2J)F1 controls. Hybrids from bm1, bm4, bm6 (all H-2Kb), and bm13 and bm14 (both H-2Db) mutants showed no differences in survival. Several of the mutant molecules differ from those of the parental strain by only one or two amino acids. Apparently, these small changes in H-2 antigens are capable of altering resistance to a histocompatible tumor to produce an immune response gene-like effect.

The availability of H-2 mutant strains and detailed data on the molecular nature of the gene products make the model presented in this report a particularly useful system to study.

1 Supported in part by Grants CA 27599, CA 27955, and AI 16919 from the NIH.

2 To whom requests for reprints should be addressed.

Received 2/16/83. Accepted 8/31/83.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.